- Home
- BORR vs ETNB Comparison
BORR vs ETNB Comparison
Compare BORR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BORR
- ETNB
- Stock Information
- Founded
- BORR 2016
- ETNB 2018
- Country
- BORR Bermuda
- ETNB United States
- Employees
- BORR N/A
- ETNB N/A
- Industry
- BORR Oil & Gas Production
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BORR Energy
- ETNB Health Care
- Exchange
- BORR Nasdaq
- ETNB Nasdaq
- Market Cap
- BORR 941.4M
- ETNB 1.0B
- IPO Year
- BORR 2019
- ETNB 2019
- Fundamental
- Price
- BORR $1.80
- ETNB $6.62
- Analyst Decision
- BORR Buy
- ETNB Strong Buy
- Analyst Count
- BORR 1
- ETNB 10
- Target Price
- BORR $9.00
- ETNB $27.56
- AVG Volume (30 Days)
- BORR 6.1M
- ETNB 2.1M
- Earning Date
- BORR 05-22-2025
- ETNB 05-08-2025
- Dividend Yield
- BORR 4.46%
- ETNB N/A
- EPS Growth
- BORR 255.56
- ETNB N/A
- EPS
- BORR 0.32
- ETNB N/A
- Revenue
- BORR $1,010,600,000.00
- ETNB N/A
- Revenue This Year
- BORR $8.35
- ETNB N/A
- Revenue Next Year
- BORR $6.39
- ETNB N/A
- P/E Ratio
- BORR $5.63
- ETNB N/A
- Revenue Growth
- BORR 30.98
- ETNB N/A
- 52 Week Low
- BORR $1.62
- ETNB $4.16
- 52 Week High
- BORR $7.26
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- BORR 41.97
- ETNB 48.00
- Support Level
- BORR $1.76
- ETNB $5.68
- Resistance Level
- BORR $2.01
- ETNB $6.13
- Average True Range (ATR)
- BORR 0.18
- ETNB 0.67
- MACD
- BORR 0.01
- ETNB 0.17
- Stochastic Oscillator
- BORR 45.83
- ETNB 83.96
Stock Price Comparison Chart: BORR vs ETNB
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).